Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Public ClinicalTrials.gov record NCT05165394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
Study identification
- NCT ID
- NCT05165394
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- NBI-1065846 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021
- Primary completion
- Jul 6, 2023
- Completion
- Sep 12, 2023
- Last update posted
- Jul 30, 2024
2021 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Birmingham | Alabama | 35294 | — |
| Neurocrine Clinical Site | Garden Grove | California | 92845 | — |
| Neurocrine Clinical Site | Lemon Grove | California | 91945 | — |
| Neurocrine Clinical Site | Orange | California | 92868 | — |
| Neurocrine Clinical Site | Riverside | California | 92506 | — |
| Neurocrine Clinical Site | San Diego | California | 92103 | — |
| Neurocrine Clinical Site | San Francisco | California | 94107 | — |
| Neurocrine Clinical Site | Orlando | Florida | 32803 | — |
| Neurocrine Clinical Site | Pensacola | Florida | 32502 | — |
| Neurocrine Clinical Site | Winter Park | Florida | 32792 | — |
| Neurocrine Clinical Site | Atlanta | Georgia | 30338 | — |
| Neurocrine Clinical Site | Chicago | Illinois | 60641 | — |
| Neurocrine Clinical Site | Skokie | Illinois | 60076 | — |
| Neurocrine Clinical Site | Saint Charles | Missouri | 63304 | — |
| Neurocrine Clinical Site | Raleigh | North Carolina | 27609 | — |
| Neurocrine Clinical Site | Columbus | Ohio | 43210 | — |
| Neurocrine Clinical Site | Oklahoma City | Oklahoma | 73112 | — |
| Neurocrine Clinical Site | Dallas | Texas | 75235 | — |
| Neurocrine Clinical Site | Friendswood | Texas | 77546 | — |
| Neurocrine Clinical Site | Houston | Texas | 77030 | — |
| Neurocrine Clinical Site | Murray | Utah | 84107 | — |
| Neurocrine Clinical Site | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05165394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2024 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05165394 live on ClinicalTrials.gov.